YM-580

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: YM-580
• 英文别名: (2R,5S)-4-(4-cyano-3-trifluoromethylphenyl)-2,5-dimethyl-N-(6-trifluoromethyl-3-pyridyl)piperazine-1-carboxamide；(2R,5S)-4-(4-cyano-3-trifluoromethylphenyl)-2,5-dimethyl-N-(6-trifluoromethyl-pyridin-3-yl)piperazine-1-carboxamide；(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide
• 化学式: C₂₁H₁₉F₆N₅O
• 分子量: 471.405
• InChiKey: JKMJQRRLCJXPOK-QWHCGFSZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  33
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  72.3
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  4-氟-2-(三氟甲基)苯甲腈 在 di-benzoyltartaric acid 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 21.17h， 生成 YM-580
  参考文献：
  名称：

  (+)-(2R,5S)-4-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an Orally Potent and Peripherally Selective Nonsteroidal Androgen Receptor Antagonist

  摘要：

  A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED50 = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.

  DOI：

  10.1021/jm050293c

文献信息

• NON-STEROIDAL ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH A PYRIDYL MOIETY
  申请人：LABRIE Fernand

  公开号：US20150175576A1

  公开（公告）日：2015-06-25

  Compounds having the structure or their salts: are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia, male baldness, muscle atrophy and weakness, sarcopenia, male hypogonadism, erectile dysfunction, female sexual dysfunction and osteoporosis. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.

  具有以下结构或其盐的化合物：用于治疗或减少患雄激素依赖性疾病的可能性，如前列腺癌、良性前列腺增生、多囊卵巢综合征、痤疮、多毛症、皮脂溢、雄激素性脱发、男性秃头、肌肉萎缩和无力、肌肉质量减少、男性性腺功能减退、勃起功能障碍、女性性功能障碍和骨质疏松症。它们可以与药学上可接受的稀释剂或载体一起配制，或以任何药物剂量形式制成。还披露了与其他活性药物成分的组合。
• Cyanophenyl derivative
  申请人：YAMANOUCHI PHARMACEUTICAL CO., LTD.

  公开号：US20040010037A1

  公开（公告）日：2004-01-15

  This application relates to a piperazino-substituted novel cyanophenyl derivative in which a substituted carbamoyl or substituted sulfamoyl group having an aryl, heterocyclic or the like group that may have a substituent group is bonded to one nitrogen atom on the piperazine ring. The compound of this application has an anti-androgen action and is useful in preventing or treating prostatic cancer, benign prostatic hyperplasia and the like diseases.

  本申请涉及一种哌嗪取代的新型氰基苯衍生物，其中取代的氨基甲酰基或取代的磺酰基团结合在哌嗪环上的一个氮原子上，该团可能具有芳基，杂环或类似的基团，可具有取代基。本申请的化合物具有抗雄激素作用，可用于预防或治疗前列腺癌，良性前列腺增生等疾病。
• CYANOPHENYL DERIVATIVES
  申请人：Astellas Pharma Inc.

  公开号：EP1122242B1

  公开（公告）日：2008-01-16
• US6673799B1
  申请人：——

  公开号：US6673799B1

  公开（公告）日：2004-01-06
• US9682960B2
  申请人：——

  公开号：US9682960B2

  公开（公告）日：2017-06-20